Literature DB >> 27646614

Prognostic impact of splenic artery invasion for pancreatic cancer of the body and tail.

Yasuyuki Fukami1, Yuji Kaneoka2, Atsuyuki Maeda2, Yuichi Takayama2, Shunsuke Onoe2.   

Abstract

BACKGROUND: The prognostic impact of splenic artery (SA) invasion after resection for pancreatic cancer of the body and tail has not been investigated. The aim of this study was to assess the clinical value of SA invasion for pancreatic cancer of the body and tail.
METHODS: Between 1993 and 2015, 64 patients who underwent distal pancreatectomy (DP) for histologically confirmed pancreatic ductal adenocarcinoma of the body and tail were included in this study. Clinicopathological prognostic factors for survival were analyzed using a prospectively collected database.
RESULTS: Of the 64 study patients, histologic invasion of the SA was confirmed in 23 (35.9%) cases. The prognosis of patients with SA invasion was significantly worse than that of patients with non-SA invasion (median survival: 16.0 versus 34.7 months, p = 0.014). Multivariate analysis indicated that lymph node metastases (risk ratio: 2.817, p = 0.005) and R1 resection (risk ratio: 2.715, p = 0.006) were independently associated with overall survival after DP for pancreatic cancer of the body and tail. In contrast, SA invasion was not extracted as an independent prognostic factor.
CONCLUSIONS: SA invasion after resection for pancreatic cancer of the body and tail does not have the prognostic impact that surpasses lymph node metastases.
Copyright © 2016 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Distal pancreatectomy; Pancreatic cancer; Splenic artery; Splenic vein

Mesh:

Year:  2016        PMID: 27646614     DOI: 10.1016/j.ijsu.2016.09.076

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  4 in total

1.  The Prognostic Impact of the Lymphocyte-to-Monocyte Ratio in Resected Pancreatic Head Adenocarcinoma.

Authors:  Shunsuke Onoe; Atsuyuki Maeda; Yuichi Takayama; Yasuyuki Fukami; Takamasa Takahashi; Masahito Uji; Yuji Kaneoka
Journal:  Med Princ Pract       Date:  2019-05-20       Impact factor: 1.927

2.  Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.

Authors:  Sanne Lof; Maarten Korrel; Jony van Hilst; Adnan Alseidi; Gianpaolo Balzano; Ugo Boggi; Giovanni Butturini; Riccardo Casadei; Safi Dokmak; Bjørn Edwin; Massimo Falconi; Tobias Keck; Giuseppe Malleo; Matteo de Pastena; Ales Tomazic; Hanneke Wilmink; Alessandro Zerbi; Marc G Besselink; Mohammed Abu Hilal
Journal:  Ann Surg Oncol       Date:  2019-12-17       Impact factor: 5.344

3.  Splenic-vasculature involvement is associated with poor prognosis in resected distal pancreatic cancer.

Authors:  Feng Yin; Mohammed Saad; Jingmei Lin; Christopher R Jackson; Bing Ren; Cynthia Lawson; Dipti M Karamchandani; Belen Quereda Bernabeu; Wei Jiang; Teena Dhir; Richard Zheng; Christopher W Schultz; Dongwei Zhang; Courtney L Thomas; Xuchen Zhang; Jinping Lai; Michael Schild; Xuefeng Zhang; Hao Xie; Xiuli Liu
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-11-24

4.  Prognostic impact of splenic vessel involvement and tumor size in distal pancreatectomy for adenocarcinoma: a retrospective multicentric cohort study.

Authors:  Dominique Gantois; Théophile Guilbaud; Ugo Scemama; Edouard Girard; Olivier Picaud; Marine Lefevre; Myriam Elgani; Zeinab Hamidou; Vincent Moutardier; Paul Balandraud; Mircea Chirica; Louise Barbier; David Fuks; David Jérémie Birnbaum
Journal:  Langenbecks Arch Surg       Date:  2021-08-10       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.